



**Chief Executive Officer**

Paul Lumley

February 7, 2024

**Board of Directors**

*Delivered verbally*

**President**

Miguel Villarreal  
Kaiser Permanente

Chair Nosse, Vice-Chairs Goodwin & Nelson, and committee members:

**Vice President**

Kris Young  
Nike

For the record, my name is Jonathan Frochtz wajg; I'm the Public-Policy Manager for Cascade AIDS Project, or CAP. Founded in 1983 as a grassroots response to the emerging AIDS crisis, CAP is now the oldest and largest provider of services for people affected by HIV in Oregon.

**Secretary**

William E. Spigner  
Nike

**Treasurer**

Edwin Kietzman  
Community Member

I am testifying today in support of House Bill 4113. There are not enough generic HIV treatment medications, so most people living with HIV rely on overpriced brand-name drugs. For some, the *only* way they can afford their meds is by using co-pay assistance to reach their annual deductible. When insurance companies don't count co-pay assistance toward consumers' deductibles, even for drugs with no generic equivalent, it puts people living with HIV at risk of falling out of treatment, and undercuts public-health efforts to end the HIV epidemic.

**At Large**

Daniel Borgen  
New Seasons Market

**At Large**

Kaydie Satein  
PeaceHealth of  
SW Washington

Insurance companies say they need co-pay assistance limits to prevent consumers from choosing brand-name and other costly drugs over generic, less costly ones. However, HB 4113 *only* prohibits co-pay assistance limits when a consumer is using the assistance for a medication that has no generic equivalent, or a medication for which the consumer has demonstrated medical need. In other words, if this bill passes, insurers will still be able to limit co-pay assistance for drugs with a generic equivalent, and insurers will still be able to use prior-authorization requirements and other utilization-management techniques to keep consumers on lower-cost drugs.

**Kate Janczyk Bowman**

Retired

**Tracy A. Curtis**

Wells Fargo Bank

**Jason H. Desilet**

OnPoint Community  
Credit Union

**Christopher Friend**

Swire Coca-Cola

**Eric Garcia**

Multnomah County

**CJ Grub**

Methinks

**Daniel Guilfoyle**

Native American Youth &  
Family Center (NAYA)

**Craig A. Kolins, PhD**

Trauma Intervention Program  
(TIP) Northwest

**Sarah Morris**

Ernst & Young, LLP

**John R. Ogden**

Kaiser Permanente

CAP supports policies that *fairly* address inflated prescription-drug prices, including establishing upper payment limits. Co-pay assistance limits, or co-pay accumulators, are not fair. Created by insurance companies, not public policymakers, they place the burden of addressing high drug prices on healthcare consumers who have chronic conditions and no good choices. A growing number of public-interest advocates support this bill; in addition to the ones you've heard from here today, these include SEIU, the Oregon Academy of Family Physicians, and the ACLU of Oregon. We hope that you will join us—thank you.

**Jeffrey W. Woodcox**

Tonkon Torp LLP

520 Northwest Davis Street, Suite 215 Portland, Oregon 97209

t > 503 223 5907

f > 503 223 6437

capnw.org